Overview

• Governor Greg Abbott plans to sign the bill authored by State Sen. Tan Parker that allocates $50 million for ibogaine clinical trials in Texas.
• The funding will support clinical trials assessing ibogaine’s potential to treat PTSD, depression and anxiety in veterans as well as addiction.
• Although federally classified as Schedule I, ibogaine has shown promise in reducing depression, suicidality and opioid withdrawal symptoms in studies at Stanford and by the Multidisciplinary Association for Psychedelic Studies.
• Ibogaine carries serious cardiac risks, including potentially life-threatening arrhythmias, and more than 30 fatalities have been linked to its use in peer-reviewed literature.
• Grant applicants must recognize Texas’s commercial interests in any patentable intellectual property arising from the trials, covering treatments, methods and related technologies.